Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 652

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 652
---
 | ​ | ​ | Number of securitiesto be issued uponexercise ofoutstanding options,warrants and rights(a) |   |         |   | ​ | ​ | Weighted-averageexercise price ofoutstanding options,warrants and rights(b)(2) |   |       |   | ​ | ​ | Number of securitiesremaining availablefor future issuanceunder equitycompensation plans(excluding shares ofcommon stockreflected in column (a))(c)(3) |   |           |   | ​ |
|:-----------------------------------------------------------|:--|:--|:-------------------------------------------------------------------------------------------|:--|--------:|:--|:--|:--|:-------------------------------------------------------------------------------|:--|------:|:--|:--|:--|:-------------------------------------------------------------------------------------------------------------------------------------------------------|:--|----------:|:--|:--|
| Equity compensation plans approved by securityholders﻿(1)  | ​ | ​ | ​                                                                                          | ​ | 420,373 | ​ | ​ | ​ | ​                                                                              | $ | 86.35 | ​ | ​ | ​ | ​                                                                                                                                                      | ​ |   494,275 | ​ | ​ |
| Equity compensation plans not approved by security holders | ​ | ​ | ​                                                                                          | ​ |       — | ​ | ​ | ​ | ​                                                                              | ​ |     — | ​ | ​ | ​ | ​                                                                                                                                                      | ​ | 25,000(4) | ​ | ​ |
| Total                                                      | ​ | ​ | ​                                                                                          | ​ | 420,373 | ​ | ​ | ​ | ​                                                                              | $ | 86.35 | ​ | ​ | ​ | ​                                                                                                                                                      | ​ |   519,275 | ​ | ​ |

374

TABLE OF CONTENTS

(1)

Includes Cara’s 2014 Plan.

(2)

Cara grants full value restricted stock units which skew the weighted average exercise price down since there is no strike price. Excluding restricted stock units, Cara had 340,460 securities issued from plans approved by security holders, comprised of stock options, with a weighted average exercise price of $106.62 per share.

(3)

All of these shares are available for future issuance under Cara’s 2014 Plan.

(4)

Includes shares of common stock issuable pursuant to Cara’s 2019 Inducement Plan (the Inducement Plan).

#### 2019 Inducement Plan
The Cara Board adopted the Inducement Plan effective as of November 20,